<\/p>\n
Glycostem and ENPICOM receive MIT Zuid subsidy to support their R&D partnership project of over half a million euro.<\/em><\/p>\n Two innovative Dutch SME’s active in Life Sciences, Glycostem Therapeutics BV and ENPICOM BV, announced that their joint MIT Zuid R&D partnership subsidy has been granted. The aim of the collaboration is to develop technology to predict the outcome of an NK-cell-based immunotherapy treatment in patients with incurable locally advanced or metastatic solid tumors, for which there is no standard therapy.<\/p>\n The predictability of outcomes of universal NK-cell therapy (oNKord\u00ae) and immune suppressive effects are needed to select the best approach in a new immunotherapy against cancer.<\/p>\n The primary goal is predicting the outcome of an NK-cell-based immunotherapy treatment in patients with incurable locally advanced or metastatic solid tumors, for which there is no standard therapy.<\/p>\n The integrated T-cell receptor and NK-cell receptor repertoire analysis developed in this project enables the development of a unique data-driven combination therapy that provides:<\/p>\n
\n<\/em>Background problem<\/h2>\n\nProject goals<\/h2>\n